Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases... Show more
The Moving Average Convergence Divergence (MACD) for JBIO turned positive on August 18, 2025. Looking at past instances where JBIO's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JBIO's RSI Oscillator exited the oversold zone, of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 21, 2025. You may want to consider a long position or call options on JBIO as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where JBIO advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
JBIO moved below its 50-day moving average on July 24, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for JBIO crossed bearishly below the 50-day moving average on July 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JBIO broke above its upper Bollinger Band on August 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JBIO entered a downward trend on August 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (19.700). P/E Ratio (0.000) is within average values for comparable stocks, (54.040). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.655). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (303.721).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
A.I.dvisor indicates that over the last year, JBIO has been closely correlated with OVID. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if JBIO jumps, then OVID could also see price increases.
Ticker / NAME | Correlation To JBIO | 1D Price Change % | ||
---|---|---|---|---|
JBIO | 100% | +1.64% | ||
OVID - JBIO | 79% Closely correlated | -0.79% | ||
KNSA - JBIO | 37% Loosely correlated | -0.59% | ||
SYRE - JBIO | 30% Poorly correlated | -2.45% | ||
KPRX - JBIO | 29% Poorly correlated | -2.80% | ||
MAIA - JBIO | 26% Poorly correlated | -7.88% | ||
More |